Bibliometric analysis and description of research trends in the treatment of psoriasis with biologic agents in the past two decades (2004–2023)

Biologics are essential in treating psoriasis. In recent years, the pathogenesis exploration and development of new target drugs have provided a more complete evidence-based foundation for the biological treatment of psoriasis. This study aims to use bibliometrics to analyze the research status and development trends of biologics in psoriasis. The bibliometric analysis of publications related to biologics in psoriasis from 2004 to 2023 was conducted using the Web of Science Core Collection (WoSCC) database as the search data source. To perform the bibliometric analysis and create visual knowledge graphs, CiteSpace, the Bibliometrix R package, and VOSviewers were utilized. The study included a total of 3800 articles. The United States had the highest number of publications. The leading authors and institutions were Steven R. Feldman and the University of Manchester, respectively, in the global partnership. The cluster plot divided all keywords into 11 categories. Currently, Secukinumab and Guselkumab are representative biological agents being studied due to their considerable efficacy and long-term safety. Targeted therapy has emerged as a significant trend in the current treatment of psoriasis. Early and active use of biologics can effectively control disease progression, prevent or delay the occurrence of comorbidities, and may even alter the natural course of psoriasis. However, further investigation is required to fully understand the specific mechanisms of psoriasis and the use of biological agents.

生物制剂（Biologics）在银屑病（psoriasis）的临床治疗中不可或缺。近年来，银屑病发病机制探索与新型靶向药物研发，为其生物治疗提供了更为完善的循证医学依据。本研究旨在采用文献计量学方法，分析银屑病领域生物制剂的研究现状与发展趋势。本研究以Web of Science核心合集（Web of Science Core Collection, WoSCC）数据库为检索数据源，对2004年至2023年间发表的银屑病生物制剂相关文献开展文献计量分析。研究采用CiteSpace、Bibliometrix R包及VOSviewers工具完成文献计量分析并绘制可视化知识图谱。本次分析共纳入3800篇文献。美国的发文量位居全球首位；在全球合作网络中，核心作者为Steven R. Feldman，主导机构为曼彻斯特大学。关键词聚类图谱将所有检索关键词划分为11个类别。当前，司库奇尤单抗（Secukinumab）与古塞奇尤单抗（Guselkumab）因疗效显著、长期安全性良好，成为该领域研究热度较高的代表性生物制剂。靶向治疗已成为银屑病治疗领域的重要发展趋势。早期积极使用生物制剂可有效控制疾病进展，预防或延缓并发症的发生，甚至可能改变银屑病的自然病程。但目前仍需开展进一步研究，以全面阐明银屑病的具体发病机制及生物制剂的临床应用方案。